RTW Investments MLYS Position
Exited6-Fund ConvergenceRTW Investments exited their position in Mineralys Therapeutics, Inc. (MLYS) in Q4 2023, after holding the stock for 4 quarters.
The position was first reported in Q1 2023 and has been tracked across 4 quarterly 13F filings.
MLYS is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 13.4% of float with 7.8 days to cover, indicating significant bearish positioning against the stock.
2 insider purchases totaling $8.8M have been filed in the last 90 days, providing an additional conviction signal.
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Full company profile →Short Interest
13.4%
7.8 days to cover
Insider Buys (90d)
2
$8.8M total
RTW Investments MLYS Position History
Frequently Asked Questions
Does RTW Investments own MLYS?
No. RTW Investments exited their position in Mineralys Therapeutics, Inc. (MLYS) in Q4 2023. They previously held the stock for 4 quarters.
How many hedge funds own MLYS?
6 specialist biotech hedge funds currently hold MLYS, including RA Capital Management, OrbiMed Advisors, Rock Springs Capital and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RTW Investments first buy MLYS?
RTW Investments's position in MLYS was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RTW Investments's MLYS position increasing or decreasing?
RTW Investments completely exited their MLYS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
MLYSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RTW InvestmentsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →